Titel: Mucin-based nanoparticles for DNA-guided intracellular drug delivery
Datum und Uhrzeit: Dienstag, 10. November 2020, 13:00 Uhr
Sprecherin: Ceren Kimna, Arbeitsgruppe „Biopoloymere und Bio-Grenzflächen” (Prof. Oliver Lieleg)
Abstract:
The targeted intracellular delivery of therapeutics to a specific disease site is still very challenging. Especially when drugs such as chemotherapeutics are used, the importance of a control mechanism that differentiates the target cells from the off-target, healthy tissue is indisputable. In this study, we designed mucin-based nanocarriers which can undergo a conformational change upon request to deliver active agents. With this strategy, we can accumulate the drug molecules in the cytosol and initiate their liberation in presence of a trigger DNA sequence. Furthermore, we demonstrate, how an endogenous marker, e.g., specific miRNA overexpression, can be used as a stimulus to autonomously initiate the intracellular drug release. We expect that this highly specific delivery mechanism can pave the way for the design of patient-tailored treatments for such diseases, where overexpression of signature oligonucleotide sequences has been identified. Original Article: https://pubs.acs.org/doi/10.1021/acsnano.0c04035
More Information
This semester, the MSB Seminar will take place online (Zoom). Please register via email (julia.knuerr(at)tum.de) and we are happy to provide the access data.
Program winter term 2020/2021
17 November 2020 | 1 pm | tbd | tbd | tbd |
24 November 2020 | 1 pm | Jose Page | Lasser Group | tbd |
1 December 2020 | 1 pm | Francisco Zurita | Wolfrum Group | Peripheral nerve modulation for tissue control |
8 December 2020 | 1 pm | tbd | tbd | tbd |
15 December 2020 | 1 pm | tbd | tbd | tbd |
12 January 2021 | 1 pm | Bojan Sandurkov | Gleich Group | tbd |
19 January 2021 | 1 pm | Albert Cronert | Hemmert Group | tbd |
26 January 2021 | 1 pm | Klaus Wagenbauer | Dietz Group | tbd |
2 February 2021 | 1 pm | Lennart Weiß | Wolfrum Group | tbd |
9 February 2021 | 1 pm | Jonathan Rapp | Gleich Group | tbd |